Eli Lilly’s GLP-1 lineup may offer a lift into Q3, analysts watching Mounjaro, Zepbound and broader access

Eli Lilly’s upcoming quarterly update will land under a familiar spotlight: how fast its GLP-1 franchise is still expanding and whether momentum can carry into the second half of the year. In a market report published on Oct. 19, the emphasis was on sales strength from the company’s established obesity and diabetes medicines and on the potential for its broader portfolio to widen its addressable market before Q3 reporting.

The report argued that continued outperformance in Eli Lilly’s GLP-1 portfolio is likely to be reflected in Q3 results, with Mounjaro and Zepbound described as the key near-term drivers. Mounjaro is Lilly’s brand for tirzepatide, approved for type 2 diabetes, while Zepbound is tirzepatide for chronic weight management. Both are part of the company’s broader push to translate demand for GLP-1-style therapies into sustained revenue growth.

Beyond the two frontline brands, the report also highlighted “Foundayo” as part of the company’s next wave of GLP-1-related growth. Foundayo is referenced in the article as an expanding market-access effort, implying that Lilly’s ability to place and sell future products more widely could matter for overall growth momentum as the quarter progresses.

That framing suggests investors will be watching not only prescription demand but also payer coverage and channel execution, since GLP-1 medicines often face reimbursement hurdles. While the article did not provide detailed insurer-by-insurer outcomes in the materials available here, it connected improved access to the prospect of a more supportive sales environment heading into Q3.

Eli Lilly’s quarter-to-quarter narrative in this space has typically hinged on two interlocking variables: whether manufacturing can keep pace with demand and whether coverage trends allow patients to start and stay on therapy. The market report’s focus on Mounjaro and Zepbound implies that Lilly’s near-term results may benefit if those variables remain favorable through the reporting period.

The report’s outlook also underscores the strategic importance of portfolio breadth for a company whose growth depends heavily on a single therapeutic class. When a GLP-1 leader can broaden coverage, add new offerings, or deepen access routes, it can reduce dependence on any one product’s uptake curve. That diversification theme is reflected in the article’s linkage of current sales momentum with future access expansion.

Still, major specifics were not disclosed in the text available for this story. The report did not provide quantified guidance, segment breakdowns, or the timeline and geography of Foundayo’s “expanding market access.” Investors will therefore need to rely on Lilly’s own Q3 materials, including management commentary, volume and prescription metrics (when provided), and any updated assumptions about demand and supply.

Heading into the earnings release, the key watch items will likely be whether Lilly confirms that GLP-1 demand remains strong enough to sustain sequential growth, and whether management offers more clarity on how access initiatives could translate into incremental sales during and after Q3. Any updated discussion of reimbursement dynamics, capacity, and product mix would be especially relevant for investors evaluating the sustainability of the GLP-1 growth story.